| Abstrakt: |
The article focuses on the action of a new sugar-lowering drug preparation glucobai (acarbose) in 47 patients with non-insulin-dependent diabetes mellitus (NIDM). The drug was prescribed at a dose of 150-300 mg daily with meal. A marked sugar-lowering effect was manifested by reduction of the level of postprandial hyperglycemia, glycosylated hemoglobin, fructosamine, body mass of the patients. The results obtained permit recommending glucobai (acarbose) as a sugar-lowering drug in NIDM patients. |
